Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:ANIPNASDAQ:CNCENASDAQ:IDYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$29.45+0.6%$30.30$23.42▼$62.58$1.69B0.83705,097 shs358,865 shsANIPANI Pharmaceuticals$69.82+0.3%$64.24$52.50▼$70.55$1.52B0.49273,758 shs205,402 shsCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/AIDYAIDEAYA Biosciences$19.00-0.4%$18.00$13.45▼$44.42$1.66B0.51954,813 shs1.69 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals0.00%+6.47%-4.51%-14.54%-7.01%ANIPANI Pharmaceuticals0.00%+0.88%+2.14%+19.07%+6.71%CNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IDYAIDEAYA Biosciences0.00%+11.24%+9.01%-19.56%-52.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.0931 of 5 stars3.32.00.04.22.60.81.9ANIPANI Pharmaceuticals4.4249 of 5 stars3.53.00.03.32.83.31.3CNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIDYAIDEAYA Biosciences3.5561 of 5 stars3.51.00.04.42.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.56Moderate Buy$56.5792.09% UpsideANIPANI Pharmaceuticals 3.00Buy$80.1314.76% UpsideCNCEConcert Pharmaceuticals 0.00N/AN/AN/AIDYAIDEAYA Biosciences 2.93Moderate Buy$53.58182.02% UpsideCurrent Analyst Ratings BreakdownLatest CNCE, IDYA, AGIO, and ANIP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$62.00 ➝ $65.004/11/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.003/17/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$94.00 ➝ $94.003/14/2025ANIPANI PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.003/12/2025ANIPANI PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$85.003/5/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$84.00 ➝ $86.003/3/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$94.00 ➝ $94.002/24/2025AGIOAgios PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$58.00 ➝ $58.002/14/2025IDYAIDEAYA BiosciencesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $50.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M46.23N/AN/A$27.02 per share1.09ANIPANI Pharmaceuticals$614.38M2.47$7.73 per share9.03$21.13 per share3.30CNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58IDYAIDEAYA Biosciences$7M237.60N/AN/A$12.10 per share1.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.342.60N/AN/A1,845.92%-2.51%-2.26%5/1/2025 (Estimated)ANIPANI Pharmaceuticals$18.78M-$1.14N/A16.58N/A-1.28%15.87%6.88%5/9/2025 (Estimated)CNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/AIDYAIDEAYA Biosciences-$274.48M-$3.30N/AN/AN/AN/A-26.74%-25.54%5/6/2025 (Estimated)Latest CNCE, IDYA, AGIO, and ANIP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37N/AN/AN/A$179.75 millionN/A5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75N/AN/AN/A$2.10 millionN/A5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80N/AN/AN/A$9.86 millionN/A2/20/2025Q4 2024AGIOAgios Pharmaceuticals-$1.69-$1.74-$0.05-$1.74$9.35 millionN/A2/13/2025Q4 2024IDYAIDEAYA Biosciences-$0.67-$1.49-$0.82-$1.49$7.00 million$7.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A11.9011.56ANIPANI Pharmaceuticals1.522.741.97CNCEConcert PharmaceuticalsN/A9.039.03IDYAIDEAYA BiosciencesN/A14.9722.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AANIPANI Pharmaceuticals76.05%CNCEConcert Pharmaceuticals70.63%IDYAIDEAYA Biosciences98.29%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.93%ANIPANI Pharmaceuticals12.70%CNCEConcert Pharmaceuticals11.33%IDYAIDEAYA Biosciences3.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.30 million54.47 millionOptionableANIPANI Pharmaceuticals60021.77 million18.36 millionOptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableIDYAIDEAYA Biosciences8087.54 million84.47 millionOptionableCNCE, IDYA, AGIO, and ANIP HeadlinesRecent News About These CompaniesGuggenheim Capital LLC Takes Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)April 26 at 4:16 AM | marketbeat.comComparing IDEAYA Biosciences (NASDAQ:IDYA) and Eagle Pharmaceuticals (NASDAQ:EGRX)April 26 at 1:11 AM | americanbankingnews.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 25 at 6:00 AM | prnewswire.comMarshall Wace LLP Buys 60,361 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)April 25 at 4:21 AM | marketbeat.comWalleye Capital LLC Has $548,000 Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)April 25 at 4:01 AM | marketbeat.comIDEAYA Biosciences (NASDAQ:IDYA) Trading Up 4.8% - What's Next?April 23, 2025 | marketbeat.comBrokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Target Price at $53.58April 23, 2025 | americanbankingnews.comRenaissance Technologies LLC Purchases 113,902 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)April 21, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by AnalystsApril 21, 2025 | marketbeat.comJump Financial LLC Has $2.95 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)April 20, 2025 | marketbeat.comJPMorgan Chase & Co. Has $7.06 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)April 19, 2025 | marketbeat.comIdeaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than LaterApril 16, 2025 | seekingalpha.comMizuho Securities Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)April 16, 2025 | markets.businessinsider.comIdeaya Biosciences announces FDA Type D meeting for darovasertib trial designApril 15, 2025 | markets.businessinsider.comIdeaya trial design consisent with guidance, says OppenheimerApril 15, 2025 | markets.businessinsider.comGeode Capital Management LLC Acquires 43,226 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)April 15, 2025 | marketbeat.comIDEAYA Biosciences begins phase 1/2 clinical trial to evaluate IDE397 and Trodelvy combination in MTAP-deletion urothelial cancerApril 15, 2025 | pharmabiz.comIDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal MelanomaApril 14, 2025 | prnewswire.comFmr LLC Acquires 327,498 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)April 13, 2025 | marketbeat.comExodusPoint Capital Management LP Sells 343,236 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)April 12, 2025 | marketbeat.comIDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial CancerApril 10, 2025 | medindia.netNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNCE, IDYA, AGIO, and ANIP Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$29.45 +0.19 (+0.65%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$28.82 -0.63 (-2.12%) As of 04/25/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.ANI Pharmaceuticals NASDAQ:ANIP$69.82 +0.18 (+0.26%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$69.82 +0.01 (+0.01%) As of 04/25/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Concert Pharmaceuticals NASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.IDEAYA Biosciences NASDAQ:IDYA$19.00 -0.07 (-0.37%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$18.98 -0.02 (-0.08%) As of 04/25/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
